Prospective monitoring of a CD4+ CD25high CD45RO+ CD127high T-cell population after first kidney transplantation following thymoglobulin or basiliximab induction
Details
Serval ID
serval:BIB_9C66A7A0B976
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Poster: Summary – with images – on one page of the results of a researche project. The summaries of the poster must be entered in "Abstract" and not "Poster".
Collection
Publications
Institution
Title
Prospective monitoring of a CD4+ CD25high CD45RO+ CD127high T-cell population after first kidney transplantation following thymoglobulin or basiliximab induction
Title of the conference
Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery
Address
Fribourg, Switzerland, April 17-18, 2008
ISBN
1424-7860
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
138
Series
Swiss Medical Weekly
Pages
57S
Language
english
Notes
Meeting Abstract
Abstract
Background: Recent data have suggested that a population of CD4+
CD25high T cells, phenotypically characterized by the expression of
CD45RO and CD127, is significantly expanded in stable liver and
kidney transplant recipients and represents alloreactive T cells.
Induction therapies may have an impact on this alloreactive T cell
population. In this study, we prospectively analyzed CD4+ CD25high
CD45RO+ CD127high T cells after induction with either
thymoglobulin or basiliximab.
Patients and methods: A total of twenty-seven kidney transplant
recipients were prospectively enrolled; 14 received thymoglobulin
induction followed by a 4-day course of steroids with tacrolimus and
mycophenolate mofetil («thymo group»), and 13 received basiliximab
induction followed by standard triple immunosuppression (tacrolimus,
mycophenolate mofetil and prednisone) («BSX group»). Phenotypical
analysis by flow cytometry of the expression of CD25, CD45RO and
CD127 on peripheral CD4+ T cells was performed at 0, 3 and 6
months after transplantation. Twenty-four healthy subjects (HS) were
studied as controls.
Results: There were no differences in baseline characteristics
between the groups; at 6 months, patient survival (100%), graft
survival (100%), serum creatinine (thymo group versus BSX group:
129 versus 125 micromol/l) and acute rejection (2/14 versus 2/13)
were not significantly different. Thymo induction produced a
prolonged CD4 T cell depletion. As compared to pre-transplantation
values, an expansion of the alloreactive T cell population was
observed at 3 months in both thymo (mean: from 6.38% to 14.72%)
and BSX (mean: from 8.01% to 18.42%) groups. At 6 months, the
alloreactive T cell population remained significantly expanded in the
thymo group (16.92 ± 2.87%) whereas it tended to decrease in the
BSX group (10.22 ± 1.38%).
Conclusion: Overall, our results indicate that the expansion of
alloreactive T cells occurs rapidly after transplantation in patients
receiving either thymo or BSX induction. Whether differences at later
timepoints or whether different IS regimens may modify this
alloreactive population remains to be studied.
CD25high T cells, phenotypically characterized by the expression of
CD45RO and CD127, is significantly expanded in stable liver and
kidney transplant recipients and represents alloreactive T cells.
Induction therapies may have an impact on this alloreactive T cell
population. In this study, we prospectively analyzed CD4+ CD25high
CD45RO+ CD127high T cells after induction with either
thymoglobulin or basiliximab.
Patients and methods: A total of twenty-seven kidney transplant
recipients were prospectively enrolled; 14 received thymoglobulin
induction followed by a 4-day course of steroids with tacrolimus and
mycophenolate mofetil («thymo group»), and 13 received basiliximab
induction followed by standard triple immunosuppression (tacrolimus,
mycophenolate mofetil and prednisone) («BSX group»). Phenotypical
analysis by flow cytometry of the expression of CD25, CD45RO and
CD127 on peripheral CD4+ T cells was performed at 0, 3 and 6
months after transplantation. Twenty-four healthy subjects (HS) were
studied as controls.
Results: There were no differences in baseline characteristics
between the groups; at 6 months, patient survival (100%), graft
survival (100%), serum creatinine (thymo group versus BSX group:
129 versus 125 micromol/l) and acute rejection (2/14 versus 2/13)
were not significantly different. Thymo induction produced a
prolonged CD4 T cell depletion. As compared to pre-transplantation
values, an expansion of the alloreactive T cell population was
observed at 3 months in both thymo (mean: from 6.38% to 14.72%)
and BSX (mean: from 8.01% to 18.42%) groups. At 6 months, the
alloreactive T cell population remained significantly expanded in the
thymo group (16.92 ± 2.87%) whereas it tended to decrease in the
BSX group (10.22 ± 1.38%).
Conclusion: Overall, our results indicate that the expansion of
alloreactive T cells occurs rapidly after transplantation in patients
receiving either thymo or BSX induction. Whether differences at later
timepoints or whether different IS regimens may modify this
alloreactive population remains to be studied.
Web of science
Create date
13/10/2009 14:29
Last modification date
20/08/2019 16:03
Usage data
